Advances in Nuclear Medicine: What Is Driving the Development of Radiopharmaceuticals?

Nuclear medicine returned to the forefront of global health discussions in 2026. Advances in diagnostic technologies, the growth of personalized oncology, and new investments in radiopharmaceuticals are driving a movement that is attracting the attention of the pharmaceutical industry, research centers, and companies in the healthcare sector.

In recent months, announcements made during the SNMMI 2026 (Society of Nuclear Medicine and Molecular Imaging) reinforced this trend. Major companies in the sector began to increase their investments in precision medicine, artificial intelligence applied to diagnostic imaging, and the development of radiopharmaceuticals, signaling a new phase for nuclear medicine.

But what is driving this advancement in nuclear medicine? And why have radiopharmaceuticals returned to the global spotlight?

What will nuclear medicine look like in 2026?

June 2026 brought important developments for the sector. During SNMMI 2026, global healthcare companies announced new investments aimed at expanding nuclear medicine, bolstering the development of solutions for more targeted diagnosis and treatment.

A GE HealthCare, for example, highlighted initiatives related to expanding access to nuclear medicine, with a focus on radiopharmaceuticals, artificial intelligence, and innovation in diagnostic imaging.

At the same time, the partnership announced between Telix Pharmaceuticals e United Imaging boosted the growth of so-called therapies theranostics, an approach that combines diagnosis and personalized treatment using radiopharmaceuticals.

In practice, these developments demonstrate that nuclear medicine is no longer viewed merely as a complementary specialty but has come to play a more strategic role within precision medicine.

What are radiopharmaceuticals, and why are they gaining traction?

Radiopharmaceuticals are medications that contain small amounts of radioactive material and are used to diagnose or treat certain diseases.

In oncology, for example, they have been gaining ground because they allow for greater precision in identifying tumors and, in some cases, targeted treatments that attack specific cells, thereby reducing damage to healthy tissue.

This advance is part of a broader transformation in modern medicine: the quest for increasingly personalized treatments.

Instead of one-size-fits-all approaches, there is growing interest in therapies that take into account the specific characteristics of the patient, the tumor, and the individual’s clinical profile.

As a result, radiopharmaceuticals have attracted more attention in recent years.

Personalized oncology is accelerating this trend

Much of the progress in nuclear medicine is directly linked to the growth of precision oncology.

With advances in biomarkers and imaging technologies, healthcare professionals are able to identify diseases in greater detail, enabling more accurate clinical decisions.

In this context, nuclear medicine becomes particularly important because it can be used for both diagnosis and treatment.

This trend is also in line with a trend observed globally: treatments that are less invasive, more targeted, and offer greater potential for personalization.

It is no coincidence that experts and companies in the sector have been paying increasing attention to radiopharmaceuticals and related therapies.

What could drive the next few years of nuclear medicine?

The trend is for growth in nuclear medicine to continue gaining momentum, especially in light of advances in personalized medicine.

Among the factors expected to drive this market are:

• expansion of targeted therapies;
• growth of personalized oncology;
• new investments in radiopharmaceuticals;
• advances in artificial intelligence applied to diagnosis;
• a greater emphasis on clinical accuracy.

In addition, regulatory initiatives in various countries have been stimulating the development and availability of radiopharmaceuticals, thereby increasing interest in the sector.

Although challenges related to costs, infrastructure, and access remain, the trends observed in 2026 indicate that nuclear medicine is likely to continue gaining ground in global healthcare.

More than just a passing trend, the advancement of radiopharmaceuticals seems to reflect a broader shift: increasingly personalized treatments will require equally precise technologies.